Loading...
•
Mar 31, 2022
CareDx Q1 2022 Earnings Report
Reported an 18% increase in revenue year-over-year, driven by growth in testing services, product revenue, and patient and digital solutions.
Key Takeaways
CareDx reported a strong first quarter in 2022, with revenue reaching $79.4 million, an 18% increase compared to the same period last year. The company saw growth across all its revenue segments, including testing services, product revenue, and patient and digital solutions. However, the company experienced a net loss of $19.6 million, a significant increase compared to the net loss of $0.7 million in the first quarter of 2021.
Total revenue reached $79.4 million, an 18% increase year-over-year.
Approximately 42,600 AlloSure and AlloMap patient results were provided.
Tx Access was incorporated into the AlloCare app to aid pre-transplant patients.
A jury found Natera made false advertising claims, awarding CareDx $44.9M in damages.
Revenue by Segment
Forward Guidance
CareDx reiterates its revenue expectations in the range of $330 million to $350 million for the full year 2022.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...